IOVANCE BIOTHERAPEUTICS INC
NASDAQ: IOVA (Iovance Biotherapeutics, Inc.)
Last update: 3 hours ago3.79
-0.04 (-1.04%)
| Previous Close | 3.83 |
| Open | 3.80 |
| Volume | 22,359,680 |
| Avg. Volume (3M) | 12,735,118 |
| Market Cap | 1,504,508,544 |
| Price / Sales | 2.95 |
| Price / Book | 1.17 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | -176.49% |
| Operating Margin (TTM) | -245.76% |
| Diluted EPS (TTM) | -1.22 |
| Quarterly Revenue Growth (YOY) | 6,798.50% |
| Total Debt/Equity (MRQ) | 7.00% |
| Current Ratio (MRQ) | 4.18 |
| Operating Cash Flow (TTM) | -334.39 M |
| Levered Free Cash Flow (TTM) | -184.76 M |
| Return on Assets (TTM) | -27.14% |
| Return on Equity (TTM) | -51.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Iovance Biotherapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.50 |
|
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.37% |
| % Held by Institutions | 81.26% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mhr Fund Management Llc | 31 Dec 2025 | 28,967,103 |
| Invenomic Capital Management Lp | 31 Dec 2025 | 11,959,505 |
| Long Focus Capital Management, Llc | 31 Dec 2025 | 8,600,000 |
| Palo Alto Investors Lp | 31 Dec 2025 | 7,116,676 |
| Hrt Financial Lp | 31 Dec 2025 | 4,356,010 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 11.00 (Barclays, 190.24%) | Buy |
| Median | 8.00 (111.08%) | |
| Low | 5.00 (Citizens, 31.93%) | Buy |
| Average | 8.00 (111.08%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 3.83 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 25 Feb 2026 | 11.00 (190.24%) | Buy | 3.83 |
| 17 Dec 2025 | 10.00 (163.85%) | Buy | 2.52 | |
| Citizens | 25 Feb 2026 | 5.00 (31.93%) | Buy | 3.83 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma |
| 16 Jan 2026 | Announcement | Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
| 12 Jan 2026 | Announcement | Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Iovance Biotherapeutics, Inc. (IOVA), Nutex Health, Inc. (NUTX), Lantheus Holdings, Inc. (LNTH), and Molina Healthcare, Inc. (MOH) |
| 19 Dec 2025 | Announcement | Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |